A Multi-Center, Randomized, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VGR-R01 in Subjects With Bietti Crystalline Dystrophy

Study Summary

This is a phase 3 study to evaluate the efficacy and safety of VGR-R01 in subjects with Bietti Crystalline Dystrophy. This is a multicenter, randomized controlled study which will enroll 45 subjects.

Interventions

Study Locations

Facility	City	State	Country
Shanghai Vitalgen Biopharma Co.,Ltd.	Shanghai	Shanghai Municipality	China

Official Trial Information

View on ClinicalTrials.gov